Small Molecule Kinase Inhibitors for the Potential Treatment of Down's Syndrome and Alzheimer's Disease and for Studies of Alternate Gene Splicing
Lead Inventor: Craig Thomas (NCATS)
Ref. No.: E-230-2009/0
Abstract: NIH investigators have discovered a series of potent, selective small molecule inhibitors of cdc2-like kinases (Clk) and dual-specificity tyrosine-regulated kinase 1A (Dyrk1A) with potential as modulators of gene splicing and for the treatment of Down's syndrome and Alzheimer's disease.
Publications:
Potent and Selective Small Molecule Inhibitors of Specific Isoforms of Cdc2-like Kinases (Clk) and Dual Specificity Tyrosine-Phosphorylation-Regulated Kinases (Dyrk) • Bioorganic & Medicinal Chemistry Letters • May 2011 • NCATS Chemical Genomics Center
Evaluation of Substituted 6-arylquinazolin-4-amines as Potent and Selective Inhibitors of Cdc2-like Kinases (Clk) • Bioorganic & Medicinal Chemistry Letters • December 2009 • NCATS Chemical Genomics Center